Analyst Price Target is $102.00
▲ +310.30% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for BioXcel Therapeutics in the last 3 months. The average price target is $102.00, with a high forecast of $140.00 and a low forecast of $60.00. The average price target represents a 310.30% upside from the last price of $24.86.
Current Consensus is
The current consensus among 10 contributing investment analysts is to buy stock in BioXcel Therapeutics. This Buy consensus rating has held steady for over two years.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.